Good morning, everyone, and how was your weekend? We hope the break was refreshing and reinvigorating. Now, though, that all-too-familiar routine of meetings and deadlines has returned. Oh no... To cope, yes, we are reaching for that treasured cup of stimulation - our choice today is Wild Mountain Blueberry - and we invite you to join us. Meanwhile, we will break slightly early for a TV taping, but will be checking our email, so if you see something interesting, please let us know. Have a great day...
Cardiome Says Merck Ends Heart Drug Development (Reuters)
Express Scripts-Medco Deal May Be Delayed By State Suit (Bloomberg News)
Glaxo Strikes Deal To Track Social Media (Reuters)
Diluted Cancer Drug Victims Want Lawsuit Reopened (Associated Press)
FDA Staff Question Benefit Of Merck And Ariad Cancer Drug (Reuters)
UCB Signs R&D Pact With Oxford University (Pharma Times)
Vioxx Probe Settlement Delayed By Pennsylvania Claim (Dow Jones)
Number Of Patents Filed By Big Pharma Fell In 2009 (Financial Times)
Medidata Is Subject Of Takeover Speculation (Outsourcing Pharma)
Abbott Deals Underscore Need To Replace Humira (Chicago Tribune)
Stryker And Synthes Settle Suit Over Poaching Employees (Mass Device)
Cipla Medpro Execs Lose Bonuses For Not Meeting Targets (Business Day)
Sigma Pharma Seeks Help To End Walkout (Australian Financial Review)
Novartis Buys Rights To ThromboGenics Eye Drug For $99M (Pharma Times)
EDITOR'S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr